ResearcherDicle UniversityNo recent work listed
Abdurrahman Işıkdoğan
Matched on ORCID iD 0000-0002-7451-7286; OpenAlex author ID A5000554665. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 4)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 14
2012: 2 papers · 2013: none · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper
Papers 5
- The Efficacy and Safety of Treatment Regimens Used in the First-Line Setting in Metastatic Pancreatic Cancer Patients: A Multicenter Real-Life Study. Last author DOI 10.1097/mpa.0000000000002167↗
- Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gem… Co-author DOI 10.1186/s12885-020-06758-9↗
- Prognostic factors for gemcitabine-refractory patients with advanced pancreatic cancer: a retrospective analysis of a multicentre study (Anatolian Society of M… Last author DOI 10.5114/wo.2014.43933↗
- Long term survivors with metastatic pancreatic cancer treated with gemcitabine alone or plus cisplatin: a retrospective analysis of an Anatolian Society of Med… Last author DOI 10.7314/apjcp.2012.13.5.1841↗
- Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multic… Last author PMID 22517701↗
Closest collaborators
The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Saadettin Kılıçkap · 2 shared papers, 2020–2022 · strength 0.22
- Paper The Efficacy and Safety of Treatment Regimens Used in the First-Line Setting in Metastatic Pancreatic Cancer Patients: … DOI 10.1097/mpa.0000000000002167↗
- Paper Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated wi… DOI 10.1186/s12885-020-06758-9↗
- Nuriye Özdemir · 3 shared papers, 2012–2020 · strength 0.14
- Paper Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated wi… DOI 10.1186/s12885-020-06758-9↗
- Paper Long term survivors with metastatic pancreatic cancer treated with gemcitabine alone or plus cisplatin: a retrospective… DOI 10.7314/apjcp.2012.13.5.1841↗
- Paper Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cispl… PMID 22517701↗
- Metin Özkan · 3 shared papers, 2012–2020 · strength 0.14
- Paper Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated wi… DOI 10.1186/s12885-020-06758-9↗
- Paper Long term survivors with metastatic pancreatic cancer treated with gemcitabine alone or plus cisplatin: a retrospective… DOI 10.7314/apjcp.2012.13.5.1841↗
- Paper Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cispl… PMID 22517701↗
- Doğan Uncu · 1 shared paper, 2022 · strength 0.13
- Nadiye Akdeniz · 1 shared paper, 2022 · strength 0.13
- Yakup Ergün · 1 shared paper, 2022 · strength 0.13
- Velı Berk · 3 shared papers, 2012–2015 · strength 0.10
- Paper Prognostic factors for gemcitabine-refractory patients with advanced pancreatic cancer: a retrospective analysis of a m… DOI 10.5114/wo.2014.43933↗
- Paper Long term survivors with metastatic pancreatic cancer treated with gemcitabine alone or plus cisplatin: a retrospective… DOI 10.7314/apjcp.2012.13.5.1841↗
- Paper Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cispl… PMID 22517701↗
- Ali̇ İnal · 3 shared papers, 2012–2015 · strength 0.10
- Paper Prognostic factors for gemcitabine-refractory patients with advanced pancreatic cancer: a retrospective analysis of a m… DOI 10.5114/wo.2014.43933↗
- Paper Long term survivors with metastatic pancreatic cancer treated with gemcitabine alone or plus cisplatin: a retrospective… DOI 10.7314/apjcp.2012.13.5.1841↗
- Paper Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cispl… PMID 22517701↗
- Fahriye Tuğba Köş · 3 shared papers, 2012–2015 · strength 0.10
- Paper Prognostic factors for gemcitabine-refractory patients with advanced pancreatic cancer: a retrospective analysis of a m… DOI 10.5114/wo.2014.43933↗
- Paper Long term survivors with metastatic pancreatic cancer treated with gemcitabine alone or plus cisplatin: a retrospective… DOI 10.7314/apjcp.2012.13.5.1841↗
- Paper Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cispl… PMID 22517701↗
- Nuri Faruk Aykan · 1 shared paper, 2020 · strength 0.09
- Türkkan Evrensel · 1 shared paper, 2020 · strength 0.09
- Şuayib Yalçın · 1 shared paper, 2020 · strength 0.09
- Mahmut Gümüş · 2 shared papers, 2012 · strength 0.05
- Paper Long term survivors with metastatic pancreatic cancer treated with gemcitabine alone or plus cisplatin: a retrospective… DOI 10.7314/apjcp.2012.13.5.1841↗
- Paper Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cispl… PMID 22517701↗
- Gamze Göksel · 1 shared paper, 2012 · strength 0.02
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.